Search
Search
About
Log in
Join
Experiences with
Abiraterone
Posts
Communities
1,285 public posts
Filter results
Docetaxel for Prostate Cancer: 'Win-Win-Win'Nick Mulcahy
How Does This Compare to
Abiraterone
? The new data prompted Sumanta K.
How Does This Compare to
Abiraterone
? The new data prompted Sumanta K.
Hidden
in
Advanced Prostate Cancer
6 years ago
SPARTAN (Apalutamide)
Note that
Abiraterone
Acetate (Zytiga) is a steroidal CYP17A1 inhibitor - not a direct androgen receptor [AR] inhibitor. The confusion is probably due to the fact that hormonal therapy in all its forms ultimately targets AR.
Note that
Abiraterone
Acetate (Zytiga) is a steroidal CYP17A1 inhibitor - not a direct androgen receptor [AR] inhibitor. The confusion is probably due to the fact that hormonal therapy in all its forms ultimately targets AR.
pjoshea13
in
Advanced Prostate Cancer
6 years ago
Recent article about Lutetium 177 treatment in advanced mCRPC by doctors at the Technical University of Munich
Eligibility criteria for 177Lu-PSMA-I&T therapy included previous treatment with
abiraterone
or enzalutamide, previous taxane-based chemotherapy or unsuitability for taxanes as well as positive 68Ga-PSMA tracer uptake of metastases in a prior PET-scan.
Eligibility criteria for 177Lu-PSMA-I&T therapy included previous treatment with
abiraterone
or enzalutamide, previous taxane-based chemotherapy or unsuitability for taxanes as well as positive 68Ga-PSMA tracer uptake of metastases in a prior PET-scan.
Hidden
in
Advanced Prostate Cancer
6 years ago
Want to take advantage of all our features? Just log in!
Log in
or
Join
How late is too late for Abiraterone?
This is important as there is a small (miniscule) chance that the NHS will agree later this year that
Abiraterone
should be given as standard front line treatment (it is under review by Govt).
This is important as there is a small (miniscule) chance that the NHS will agree later this year that
Abiraterone
should be given as standard front line treatment (it is under review by Govt).
Jlcwonderboy
in
Advanced Prostate Cancer
6 years ago
Interesting result for BRCA patients from ASCO2018
"Effect of germline DNA repair gene mutations on outcomes in men with metastatic castration-resistant prostate cancer receiving first-line
abiraterone
and enzalutamide."
"Effect of germline DNA repair gene mutations on outcomes in men with metastatic castration-resistant prostate cancer receiving first-line
abiraterone
and enzalutamide."
snoraste
in
Advanced Prostate Cancer
6 years ago
Quality of Life Follow up LATITUDE trial (Zytiga+Prednisone+ADT)
In LATITUDE, 1199 patients were randomized to ADT plus
abiraterone
/prednisone (597) or to ADT plus placebo (602). Median follow-up in the ADT plus
abiraterone
/prednisone group was 30.9 months; in the ADT plus placebo group, it was 29.7 months.
In LATITUDE, 1199 patients were randomized to ADT plus
abiraterone
/prednisone (597) or to ADT plus placebo (602). Median follow-up in the ADT plus
abiraterone
/prednisone group was 30.9 months; in the ADT plus placebo group, it was 29.7 months.
snoraste
in
Advanced Prostate Cancer
6 years ago
ASCO Genitourinary Cancers Symposium (Zytiga & radiation in highish-risk local PCa.)
Men received 6 months of ADT concurrently with 1000mg AA/5mg P {
abiraterone
acetate plus prednisone} daily and 78 Gy RT to prostate/SV. Primary endpoint was PSA , 0.1 ng/ml at 1 year."
Men received 6 months of ADT concurrently with 1000mg AA/5mg P {
abiraterone
acetate plus prednisone} daily and 78 Gy RT to prostate/SV. Primary endpoint was PSA , 0.1 ng/ml at 1 year."
pjoshea13
in
Advanced Prostate Cancer
6 years ago
ASCO Genitourinary Cancers Symposium (Statin use & outcomes.)
{prednisone (P),
abiraterone
(AA)} -Patrick 230 Poster Session (Board #L6), Thu, 11:30 AM-1:00 PM and 5:15 PM-6:15 PM Impact of statins on outcomes in patients (pts) with metastatic castration resistant prostate cancer (mCRPC): Post-hoc analysis of data from COU-AA-301 and COU-AA-302 trials.
{prednisone (P),
abiraterone
(AA)} -Patrick 230 Poster Session (Board #L6), Thu, 11:30 AM-1:00 PM and 5:15 PM-6:15 PM Impact of statins on outcomes in patients (pts) with metastatic castration resistant prostate cancer (mCRPC): Post-hoc analysis of data from COU-AA-301 and COU-AA-302 trials.
pjoshea13
in
Advanced Prostate Cancer
6 years ago
ASCO Genitourinary Cancers Symposium (Statins again)
"Although limited by sample size, our data showed a trend that statins may mildly enhance the anti-tumor effects of Ab {
abiraterone
}i in CRPC patients.
"Although limited by sample size, our data showed a trend that statins may mildly enhance the anti-tumor effects of Ab {
abiraterone
}i in CRPC patients.
pjoshea13
in
Advanced Prostate Cancer
6 years ago
ASCO Genitourinary Cancers Symposium (Low testosterone at first PSA failure)
Given prolonged survival when
abiraterone
or docetaxel is added to ADT in men with castrate-sensitive metastatic prostate cancer and possibly in men with localized high-risk prostate cancer provides rationale to support their use with ADT in men with low testosterone at PSA failure in the setting of
Given prolonged survival when
abiraterone
or docetaxel is added to ADT in men with castrate-sensitive metastatic prostate cancer and possibly in men with localized high-risk prostate cancer provides rationale to support their use with ADT in men with low testosterone at PSA failure in the setting of
pjoshea13
in
Advanced Prostate Cancer
6 years ago
Finally, Real Promise' for Prostate Cancers With No Therapy20+-Month Improvement in Metastasis-Free Survival
Of those whose disease progressed, 80% of patients who were given placebo and 56% of patients who were given apalutamide received open-label
abiraterone
(Zytiga, Janssen-Cilag) for metastatic castrate-resistant prostate cancer.
Of those whose disease progressed, 80% of patients who were given placebo and 56% of patients who were given apalutamide received open-label
abiraterone
(Zytiga, Janssen-Cilag) for metastatic castrate-resistant prostate cancer.
Hidden
in
Advanced Prostate Cancer
6 years ago
ASCO Genitourinary Cancers Symposium (Xofigo - Radium-223 retreatment)
No concomitant cytotoxic agents were allowed; other concomitant agents (eg,
abiraterone
, enzalutamide) were allowed at investigator discretion. The primary objective was safety.
No concomitant cytotoxic agents were allowed; other concomitant agents (eg,
abiraterone
, enzalutamide) were allowed at investigator discretion. The primary objective was safety.
pjoshea13
in
Advanced Prostate Cancer
6 years ago
ASCO Genitourinary Cancers Symposium (Olaparib and Durvalumab in metastatic castrate-resistant prostate cancer (mCRPC))
Prior treatment with enzalutamide and/or
abiraterone
is required. D is given at 1500 mg iv q28 days + O 300 mg tablets po q12 hours. The primary endpoint is PFS. Core biopsies undergo mutational analysis.
Prior treatment with enzalutamide and/or
abiraterone
is required. D is given at 1500 mg iv q28 days + O 300 mg tablets po q12 hours. The primary endpoint is PFS. Core biopsies undergo mutational analysis.
pjoshea13
in
Advanced Prostate Cancer
6 years ago
Adding PARP inhibitor (Olaparib) to the Standard Therapy (Zytiga/ADT/Prenosone)
He admitted they are real risks, but pointed out that they had the same concerns with adding docetaxel and
abiraterone
in STAMPEDE and LATITUDE trials which were proven wrong. PARP inhibitors are also "generally" well tolerated.
He admitted they are real risks, but pointed out that they had the same concerns with adding docetaxel and
abiraterone
in STAMPEDE and LATITUDE trials which were proven wrong. PARP inhibitors are also "generally" well tolerated.
snoraste
in
Advanced Prostate Cancer
6 years ago
FDA approves Abiraterone/prednisone
http://www.janssen.com/zytiga-
abiraterone
-acetate-plus-prednisone-approved-treatment-earlier-form-metastatic-prostate
http://www.janssen.com/zytiga-
abiraterone
-acetate-plus-prednisone-approved-treatment-earlier-form-metastatic-prostate
dockam
in
Advanced Prostate Cancer
6 years ago
I'm still going strong!
After a few weeks on Casodex, changed to
Abiraterone
, Goserlin (Zoladex). I have also had Radium 223. PSA fell initially to 0 then has risen slowly. Last reading 22. Most recent scans show no organ or soft tissue involvement. My consultant says that I am doing remarkably well.
After a few weeks on Casodex, changed to
Abiraterone
, Goserlin (Zoladex). I have also had Radium 223. PSA fell initially to 0 then has risen slowly. Last reading 22. Most recent scans show no organ or soft tissue involvement. My consultant says that I am doing remarkably well.
NiallMcC
in
Advanced Prostate Cancer
6 years ago
Gleason 9, PSMA shows positive lymph nodes, surgery (plus adjuvant adt & radiation) or just adt and radiation?
Since PSMA is so new, there's not a lot of studies on what to do with confirmed LN+ One other idea I had was to try and get
abiraterone
with the radiation and ADT like the STAMPEDE trial did in Dr James' July 2017 NEJM article.
Since PSMA is so new, there's not a lot of studies on what to do with confirmed LN+ One other idea I had was to try and get
abiraterone
with the radiation and ADT like the STAMPEDE trial did in Dr James' July 2017 NEJM article.
BruceSF
in
Advanced Prostate Cancer
6 years ago
Interesting PSA progression on STAMPEDE Zytiga (Abiraterone) trial.
Hi All A couple of months ago, I was asked if my PSA results were accurate, as I was quoting from memory, and it was 6 years ago. Anyway, today I got a definitive answer from my Oncologist, and I think they make interesting reading. First PSA test at doctors 12/11/2011 PSA 443.9 First PSA test at Oncology
Hi All A couple of months ago, I was asked if my PSA results were accurate, as I was quoting from memory, and it was 6 years ago. Anyway, today I got a definitive answer from my Oncologist, and I think they make interesting reading. First PSA test at doctors 12/11/2011 PSA 443.9 First PSA test at Oncology
TommyTV
in
Advanced Prostate Cancer
6 years ago
AR-V7, Zytiga(abiraterone) and Xtandi (enzalutamide)
According so some studies, 40-50 percent of patients receiving any of the above drugs do not respond well or develop resistance in about one year. I am curious to know if any of you who are already taken these drugs know whether you have been genetically screened for the presence or absence of AR-V7
According so some studies, 40-50 percent of patients receiving any of the above drugs do not respond well or develop resistance in about one year. I am curious to know if any of you who are already taken these drugs know whether you have been genetically screened for the presence or absence of AR-V7
Cmdrdata
in
Advanced Prostate Cancer
6 years ago
thoughts from a newby
Maybe a dropdown menu to help beginners, something like: Abbreviations etc Clinical name first (
abiraterone
), brand name second (Zytiga) varies by country PCa prostate cancer ADT androgen deprivation therapy mCRPC metastatic castration-resistant Prostate Cancer mets metastases bicalutamide
Maybe a dropdown menu to help beginners, something like: Abbreviations etc Clinical name first (
abiraterone
), brand name second (Zytiga) varies by country PCa prostate cancer ADT androgen deprivation therapy mCRPC metastatic castration-resistant Prostate Cancer mets metastases bicalutamide
rpol
in
Advanced Prostate Cancer
6 years ago
1
...
59
60
61
...
65
Next page
20
30
40
50
60
Filter results
Clear filters
Posted in
All communities
Advanced Prostate Cancer
1208 results
Fight Prostate Cancer
51 results
Prostate Cancer Network
9 results
View top 10 communities
Sort by
Most Relevant
Newest